Vixotrigine is under clinical development by Biogen and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Vixotrigine’s likelihood of approval (LoA) and phase transition for Trigeminal Neuralgia (Tic Douloureux) took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vixotrigine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Vixotrigine overview

Vixotrigine (CNV-1014802, GSK-1014802) is under development for the treatment of trigeminal neuralgia. The drug candidate is administered orally. It targets voltage-gated sodium channel type IX alpha subunit (SCN9A or Nav1.7). The drug candidate is based upon ion channel electrophysiology and ion channel medicinal chemistry.

The drug candidate was also under development for the treatment of neuropathic pain associated with lumbosacral radiculopathy (PLSR) (sciatica), erythromelalgia, primary inherited, pain associated with small fiber neuropathy (SFN) in diabetes mellitus patients.

Biogen overview

Biogen is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. The company’s marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Fampyra (prolonged-release fampridine tablets), and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. It has several product candidates targeting various indications such as MS, Parkinson’s disease, CNS and neuromuscular disorders, Alzheimer’s disease, and idiopathic pulmonary fibrosis and stroke. The company sells its products through direct sales force, marketing groups, and distributors in the Americas, Europe, Asia, and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

Quick View Vixotrigine LOA Data

Report Segments
  • Innovator
Drug Name
  • Vixotrigine
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
Key Developers
  • Sponsor Company: Biogen
  • Originator: GSK
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.